The potential target PPI network of HLXLD in the treatment of psoriasis (Figure 3) had selected the core targets by topological analysis (Figure 4), indicating that HLXLD may treat psoriasis by acting on core targets such as AKT1, TNF, IL6, TP53, VEGFA, JUN, CASP3, IL1β, STAT3, PTGS2, HIF1A, EGF, MYC, EGFR, MMP9, and PPARG. This evidence concerns the gene IL1B and psoriasis.